

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person* <b>GOLDBERG MURRAY A</b> _____ (Last) (First) (Middle) <b>777 OLD SAW MILL RIVER ROAD</b> _____ (Street) <b>TARRYTOWN NY 10591</b> _____ (City) (State) (Zip)			2. Issuer Name and Ticker or Trading Symbol <b>REGENERON PHARMACEUTICALS INC [ REGN ]</b>		5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <b>SVP Finance and Admin CFO Trea</b>	
			3. Date of Earliest Transaction (Month/Day/Year) <b>11/13/2012</b>			
			4. If Amendment, Date of Original Filed (Month/Day/Year)		6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person	

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	11/13/2012		M <sup>(1)</sup>		4,745	A	\$65.76	95,259	D	
Common Stock	11/13/2012		F <sup>(1)</sup>		2,128	D	\$146.6	93,131	D	
Common Stock	11/13/2012		F <sup>(1)</sup>		1,205	D	\$146.6	91,926	D	
Common Stock	11/13/2012		M <sup>(1)</sup>		3,431	A	\$8.5	95,357	D	
Common Stock	11/13/2012		F <sup>(1)</sup>		198	D	\$146.6	95,159	D	
Common Stock	11/13/2012		F <sup>(1)</sup>		1,489	D	\$146.6	93,670	D	
Common Stock	11/13/2012		S <sup>(1)</sup>		200	D	\$144.36	93,470	D	
Common Stock	11/13/2012		S <sup>(1)</sup>		300	D	\$145.65 <sup>(2)</sup>	93,170	D	
Common Stock	11/13/2012		S <sup>(1)</sup>		1,400	D	\$146.58 <sup>(3)</sup>	91,770	D	
Common Stock	11/13/2012		S <sup>(1)</sup>		3,845	D	\$147.62 <sup>(4)</sup>	87,925	D	
Common Stock	11/13/2012		S <sup>(1)</sup>		792	D	\$148.05 <sup>(5)</sup>	87,133	D	
Common Stock	11/14/2012		S <sup>(1)</sup>		1,556	D	\$147.65 <sup>(6)</sup>	85,577	D	
Common Stock	11/14/2012		S <sup>(1)</sup>		900	D	\$148.65 <sup>(7)</sup>	84,677	D	
Common Stock	11/14/2012		S <sup>(1)</sup>		700	D	\$149.18 <sup>(8)</sup>	83,977	D	
Common Stock								5,560	I	By 401(k) Plan

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Non-Qualified Stock Option (right to buy)	\$8.5	11/13/2012		M <sup>(1)</sup>		3,431		(9)	12/20/2012	Common Stock	3,431	(10)	0.0	D	

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned  
(e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Non-Qualified Stock Option (right to buy)	\$65.76	11/13/2012		M <sup>(1)</sup>			4,745	09/06/2011	12/20/2012	Common Stock	4,745	(10)	0.0	D	

**Explanation of Responses:**

- Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
- Represents volume-weighted average price of sales of 300 shares of Company stock on November 13, 2012 at prices ranging from \$145.47 to \$145.76. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 13, 2012 at each separate price.
- Represents volume-weighted average price of sales of 1,400 shares of Company stock on November 13, 2012 at prices ranging from \$146.00 to \$146.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 13, 2012 at each separate price.
- Represents volume-weighted average price of sales of 3,845 shares of Company stock on November 13, 2012 at prices ranging from \$147.00 to \$147.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 13, 2012 at each separate price.
- Represents volume-weighted average price of sales of 792 shares of Company stock on November 13, 2012 at prices ranging from \$148.00 to \$148.12. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 13, 2012 at each separate price.
- Represents volume-weighted average price of sales of 1,556 shares of Company stock on November 14, 2012 at prices ranging from \$147.27 to \$147.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 14, 2012 at each separate price.
- Represents volume-weighted average price of sales of 900 shares of Company stock on November 14, 2012 at prices ranging from \$148.19 to \$148.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 14, 2012 at each separate price.
- Represents volume-weighted average price of sales of 700 shares of Company stock on November 14, 2012 at prices ranging from \$149.04 to \$149.54. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 14, 2012 at each separate price.
- The option became exercisable with respect to all shares underlying the option upon the satisfaction by the company of certain performance criteria on February 10, 2012.
- Exercisable date, exercise date, exercise price, purchase price, sales price, and/or expiration date is/are not applicable in this case.

By: /s/\*\*Douglas McCorkle      11/15/2012  
For: /s/\*\*Murray A. Goldberg

\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**

POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby constitutes and appoints each of Leonard Schleifer, , Beverly Dubs, Stuart Kolinski, Murray Goldberg, and Douglas McCorkle signing singly, the undersigned's true and lawful attorney-in-fact to:

- (1) execute for and on behalf of the undersigned in the undersigned's capacity as a director of Regeneron Pharmaceuticals, Inc. (the "Company"), Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;
- (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5, complete and execute any amendment or amendments thereto, and timely file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and
- (3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 12th day of September, 2005.

\*\*/s/Murray A. Goldberg

-----  
Signature

Murray A. Goldberg

-----  
Print Name